Model Could Help Identify Who May Respond to Checkpoint Inhibition in Melanoma

Source: Cancer Therapy Advisor, April 2020

The combination of radiomics and a blood marker-based prediction model may help to distinguish pseudoprogression from true progressive disease among patients with metastatic melanoma being treated with immune checkpoint inhibition, according to the results of a recent study.

According to authors, about one-half of patients with metastatic melanoma will not respond to immune checkpoint inhibition. Because of that, predictive biomarkers are needed to aid in patient selection.

In this study, researchers assessed PET/CT-based radiomics, lesion volume, and routine blood markers for use in the differentiation of psuedoprogression and true disease progression at 3 months. The study included 112 patients with a median follow-up of 22 months.